Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other...

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Multiple myeloma (MM) treatments often lack specificity beyond plasma cell (PC) neoplasias.
• Current therapies target PC biology but not specific oncogenic mutations in MM.
• There is a need for novel therapeutic targets in MM.

Purpose of the Study:

• To systematically characterize lineage-preferential molecular dependencies in MM.
• To identify novel genes critical for MM cell fitness.
• To discover therapeutic targets not readily identifiable by standard profiling methods.

Main Methods:

• Genome-scale CRISPR screens were performed in 19 MM cell lines and hundreds of non-MM lines.
• Functional genomics approaches were employed to assess gene disruption effects on cell fitness.
• Comparative analysis was conducted to identify MM-specific dependencies.

Main Results:

• 116 genes were identified whose disruption significantly impacts MM cell fitness compared to other malignancies.
• These genes include transcription factors, chromatin modifiers, ER components, metabolic regulators, and signaling molecules.
• Many identified genes are not among the commonly amplified, overexpressed, or mutated genes in MM.

Conclusions:

• Functional genomics defines novel, lineage-preferential therapeutic targets for multiple myeloma.
• These targets are largely independent of common genetic alterations in MM.
• This approach expands the repertoire of potential MM drug targets beyond conventional genomic analyses.